Effector membrane translocation biosensors reveal G protein and βarrestin coupling profiles of 100 therapeutically relevant GPCRs
Charlotte Avet,
Arturo Mancini,
Billy Breton,
Christian Le Gouill,
Alexander S Hauser,
Claire Normand,
Hiroyuki Kobayashi,
Florence Gross,
Mireille Hogue,
Viktoriya Lukasheva,
Stéphane St-Onge,
Marilyn Carrier,
Madeleine Héroux,
Sandra Morissette,
Eric B Fauman,
Jean-Philippe Fortin,
Stephan Schann,
Xavier Leroy,
David E Gloriam,
Michel Bouvier
Affiliations
Charlotte Avet
Institute for Research in Immunology and Cancer (IRIC), and Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, Canada
Arturo Mancini
Domain Therapeutics North America, Montréal, Canada
Billy Breton
Domain Therapeutics North America, Montréal, Canada
Christian Le Gouill
Institute for Research in Immunology and Cancer (IRIC), and Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, Canada
Institute for Research in Immunology and Cancer (IRIC), and Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, Canada
Florence Gross
Domain Therapeutics North America, Montréal, Canada
Mireille Hogue
Institute for Research in Immunology and Cancer (IRIC), and Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, Canada
Viktoriya Lukasheva
Institute for Research in Immunology and Cancer (IRIC), and Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, Canada
Stéphane St-Onge
Institute for Research in Immunology and Cancer (IRIC), and Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, Canada
Marilyn Carrier
Institute for Research in Immunology and Cancer (IRIC), and Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, Canada
Madeleine Héroux
Institute for Research in Immunology and Cancer (IRIC), and Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, Canada
Sandra Morissette
Domain Therapeutics North America, Montréal, Canada
Eric B Fauman
Internal Medicine Research Unit, Pfizer Worldwide Research, Development and Medical, Cambridge, United States
Institute for Research in Immunology and Cancer (IRIC), and Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, Canada
The recognition that individual GPCRs can activate multiple signaling pathways has raised the possibility of developing drugs selectively targeting therapeutically relevant ones. This requires tools to determine which G proteins and βarrestins are activated by a given receptor. Here, we present a set of BRET sensors monitoring the activation of the 12 G protein subtypes based on the translocation of their effectors to the plasma membrane (EMTA). Unlike most of the existing detection systems, EMTA does not require modification of receptors or G proteins (except for Gs). EMTA was found to be suitable for the detection of constitutive activity, inverse agonism, biased signaling and polypharmacology. Profiling of 100 therapeutically relevant human GPCRs resulted in 1500 pathway-specific concentration-response curves and revealed a great diversity of coupling profiles ranging from exquisite selectivity to broad promiscuity. Overall, this work describes unique resources for studying the complexities underlying GPCR signaling and pharmacology.